Bristol Myers Squibb (BMS) has reported a 9% growth in revenue to $46.4bn for full-year 2021 compared with $42.52 in 2020.
During the year, net product sales surged to $45.1bn from $41.3 in 2020.
Furthermore, the company’s revenue in the fourth quarter (Q4) of 2021 was $12bn, indicating a growth of 8% from 11.07bn.
The rise in revenue in the quarter was driven by the company’s Eliquis, immuno-oncology and novel product portfolios.
JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Investment Trust’s multi-asset investing approach aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly. This provides an attractive income investing and capital growth opportunity while seeking to maintain lower levels of portfolio volatility than a traditional equity portfolio.